The FDA has approved Fluarix Quadrivalent Influenza Virus Vaccine from Glaxo Smith Kline, for the immunisation of children (three years...
GlaxoSmithKline presented at the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices meeting that Fluarix Quadrivalent...
FDA expands approval of Fluarix Quadrivalent to anyone 6 months and older for influenza.
GSK announced the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK. Following a decentralised procedure,...
GSK announced the expanded indication for Fluarix Tetra (Quadrivalent Influenza Vaccine) has been approved in Europe to include adults and...
GlaxoSmithKline announced that the FDA has approved FluLaval Quadrivalent influenza Virus Vaccine for the active immunization of persons three years...
Fluarix Tetra is indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus lineages contained in the vaccine (see section 5.1). The use of Fluarix Tetra should be based on official recommendations. Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus might change from year to year.
GlaxoSmithKline announced new data published in The Lancet Child & Adolescent Health from a Phase III clinical trial with Fluarix...
The FDA has approved FluMist Quadrivalent,from Medimmune a vaccine to prevent seasonal influenza in people ages 2 years through 49...
The FDA has approved its quadrivalent formulation of Flublok influenza vaccine, from Protein Sciences Corporation. Flublok Quadrivalent protects against 4...